Dose Selection for a Direct and Selective Factor IXa Inhibitor and its Complementary Reversal Agent: Translating Pharmacokinetic and Pharmacodynamic Properties of the REG1 System to Clinical Trial Design
Thomas J. Povsic, Richard C. Becker(Clinical Research Institute), Steven L. Zelenkofske(Novartis (Switzerland)), William A. Wargin(Ottawa Hospital), Robert A. Harrington(Clinical Research Institute), John H. Alexander(Ohio State University Hospital), Mark Y. Chan(National University Heart Centre Singapore), Christopher P. Rusconi(University of North Carolina at Chapel Hill), Mauricio G. Cohen(Santa Ana College)
Cited by 26
Related Papers
Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes
|New England Journal of Medicine|2009|7.1k
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
|New England Journal of Medicine|2018|3.5k
Valsartan, Captopril, or Both in Myocardial Infarction Complicated by Heart Failure, Left Ventricular Dysfunction, or Both
|New England Journal of Medicine|2003|2.5k
Relation between Renal Dysfunction and Cardiovascular Outcomes after Myocardial Infarction
|New England Journal of Medicine|2004|1.9k